

August 10, 2001

PRELIMINARY AMENDMENT
Patent Application
Docket No. GJE-136D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Marianne Langston, Hooshang Shahriari Zavareh
Docket No. : GJE-136D1
For : The Manufacture of Single Isomer Methylphenidate

Box PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

It is respectfully requested that the above-identified patent application be amended as follows:

In the Specification

Please insert the following new paragraph after the Title of the invention on page 1, line 2:

Cross-Reference to Related Applications

This application is a continuation of U.S. application Serial No. 08/792,415, filed February 3, 1997, which claims priority from U.S. Provisional Application Serial No. 60/021,135, filed September 12, 1996, now abandoned.

Please substitute the following paragraph on page 1, beginning at line 8:

Methylphenidate was first prepared as a mixture of the *erythro* [R^*S^*] and *threo* [R^*R^*] racemates. US-A-2957880 discloses studies upon the two racemic mixtures, which revealed that the therapeutic activity resides in the *threo* diastereoisomer. It is now considered that it is the *d-threo* [or (*R,R*)] enantiomer that has the preferred therapeutic activity. Uses of this enantiomer are disclosed in PCT/GB96/01688 (International Publication No. WO 97/03671), PCT/GB96/01689 (International Publication No. WO 97/03672) and PCT/GB96/01690 (International Publication No. WO 97/03673), the contents of which are incorporated herein by reference.

Please substitute the following paragraph on page 4, beginning at line 14:

- 1) Resolve *dl-threo*-methylphenidate by the procedure described in the Example of PCT/GB97/00185 (International Publication No. WO 97/27176).

Remarks

The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Respectfully submitted,



Doran R. Pace
Patent Attorney
Registration No. 38,261
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

DRP/sl

Attachment: Marked-Up Version of Substituted Paragraphs

Marked-Up Version of Substituted Paragraphs

Paragraph on page 1, beginning at line 8:

Methylphenidate was first prepared as a mixture of the *erythro* [R^*S^*] and *threo* [R^*R^*] racemates. US-A-2957880 discloses studies upon the two racemic mixtures, which revealed that the therapeutic activity resides in the *threo* diastereoisomer. It is now considered that it is the *d-threo* [or (R,R)] enantiomer that has the preferred therapeutic activity. Uses of this enantiomer are disclosed in PCT/GB96/01688 (International Publication No. WO 97/03671), PCT/GB96/01689 (International Publication No. WO 97/03672) and PCT/GB96/01690 (International Publication No. WO 97/03673), the contents of which are incorporated herein by reference.

Paragraph on page 4, beginning at line 14:

- 1) Resolve *dl-threo*-methylphenidate by the procedure described in the Example of PCT/GB97/00185 (International Publication No. WO 97/27176).